ArticleEmerging microbes & infections2025
Influenza A hemagglutinin virus-like particles confer protection against influenza B virus infection.
Article in Emerging microbes & infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Influenza mRNA vaccine with engineered panhandle-forming UTRs provides potent, dose-sparing protection against seasonal influenza viruses.NPJ vaccines · 2026Article
- Hemagglutinin-displaying influenza nanovaccines: progress and promise.Nanomedicine (London, England) · 2026Review
- Development of a rapid, sensitive and visual reverse transcription recombinase-aided amplification coupled with lateral flow dipstick assay for influenza B virus detection.Frontiers in microbiology · 2026Article
- Advances and prospects of respiratory mucosal vaccines: mechanisms, technologies, and clinical applications.NPJ vaccines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza A hemagglutinin (HA), neuraminidase, and/or M2e-containing virus-like particles (VLPs) induce immune responses that contribute to protection against multiple influenza A virus subtypes. In this study, we investigated the protective efficacy of influenza A/H1H3 VLPs against influenza B virus infections (B/Colorado/06/2017 and B/Malaysia/2506/2004, Victoria lineage) in mice. A/H1H3 VLP immunization elicited protection against lethal challenge infections with both B/Colorado and B/Malaysia, significantly reducing lung viral loads and ensuring 100% survival of immunized mice. Sera from A/H1H3VLP-immunized mice recognized inactivated B/Colorado and B/Malaysia virus antigens and enhanced Fc receptor-mediated antibody-dependent cellular cytotoxicity (ADCC) responses. Notably, immune sera reacted with HA, HA1, and HA2 antigens from both B/Colorado and B/Malaysia viruses. A/H1H3VLP immunization also induced lung IgG and IgA antibody responses against HA, HA1, and HA2 of both B viruses, as well as antibody-secreting cell responses (ASC), germinal center B (GC B) responses, and CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.